TessArae | GenomeWeb

TessArae

While ethnicity-based screening remains the consensus approach for identifying disease-causing mutations, the American population is becoming increasingly admixed, meaning that genetic laboratories often have to run multiple panels on the same individual.

NEW YORK (GenomeWeb News) – TessArae and Kindstar Global today announced a collaboration to develop genetic tests for the Chinese population.

Galil Genetic Analysis recently began offering its OncoGenetics RDMGGA 1.0 Re-sequencing Chip as a service to its customers in Israel, according to the company's CEO.

IP Roundup

Premium

Callida Genomics, Illumina, SRU Biosystems, George Mason University, Receptors, TessArae, Affymetrix

People in the News

Premium

Thomas Richards, Ronald Davis

The partnership is one of several for TessArae, which has traditionally served the infectious disease-testing market, but has recently begun offering services to genetic disease-testing firms.

The vote of confidence is a stepping stone for the company to seek 510(k) approval for an H1N1 test on its platform; to tackle the point-of-care diagnostic market; and to further develop tests for other infectious diseases.

By obtaining emergency use authorization from the FDA, Potomac Falls, Va.-based TessArae becomes the first array firm to have received an EUA to sell chips for the monitoring and early diagnosis of the H1N1 influenza A virus.

The assay was developed through Affymetrix's MyGeneChip Custom Array Program. It is the latest in a series of molecular diagnostic products to get an FDA EUA.

For TessArae, which specializes in developing pathogen-detection arrays, the deal with GeneDx is the first of its kind. The company said this week that it intends to pursue more opportunities in the genetic disease-testing arena.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.